Tresyl-monomethoxypolyethylene glycol-modified viruses having viral infectivity
US6569426B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Sep 30, 1999 |
| Grant date | May 27, 2003 |
| Priority date | — |
| Expiry date | Sep 30, 2019 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/81
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Viruses are modified by coupling a polymer such as polyethylene glycol to obtain polymer-modified viruses that can exhibit reduced antigenicity while retaining infectivity, and which may exhibit increased circulation time in vivo. The polymer may be directly covalently attached or indirectly covalently attached via an intermediate coupling moiety to the virus. The polymer may also be indirectly noncovalently attached to the virus via a ligand such as an antibody having specificity for a viral surface component. To prepare the polymer-modified virus, the polymer is activated and coupled to the virus. A preferred activated polymer is tresyl-monomethoxypolyethylene glycol having an average molecular weight of about 5000 daltons. The polymer-modified viruses have utility for therapeutic and diagnostic in vivo applications, and may be used to introduce a transgene into a target cell by infection, or be administered to a subject having a tumor where the polymer-modified virus localizes to the tumor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.